Cargando…

A clinically relevant gene signature in triple negative and basal-like breast cancer

INTRODUCTION: Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are most useful in ER-positive cancers. Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rody, Achim, Karn, Thomas, Liedtke, Cornelia, Pusztai, Lajos, Ruckhaeberle, Eugen, Hanker, Lars, Gaetje, Regine, Solbach, Christine, Ahr, Andre, Metzler, Dirk, Schmidt, Marcus, Müller, Volkmar, Holtrich, Uwe, Kaufmann, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262210/ https://www.ncbi.nlm.nih.gov/pubmed/21978456 http://dx.doi.org/10.1186/bcr3035

Ejemplares similares

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
por: Rody, Achim, et al.
Publicado: (2009)

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
por: Karn, Thomas, et al.
Publicado: (2011)

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer
por: Karn, Thomas, et al.
Publicado: (2014)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
por: Bianchini, Giampaolo, et al.
Publicado: (2013)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
por: Hanker, L. C., et al.
Publicado: (2021)

Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer
por: Győrffy, Balázs, et al.
Publicado: (2015)

Treatment of Recurrent Epithelial Ovarian Cancer
por: Claussen, Carlota, et al.
Publicado: (2020)

Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines
por: Bräutigam, Karen, et al.
Publicado: (2021)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Evaluation of biological pathways involved in chemotherapy response in breast cancer
por: Tordai, Attila, et al.
Publicado: (2008)

Primary ovarian leiomyoma: a rare ovarian tumour
por: Pervan, Mascha, et al.
Publicado: (2022)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Impact of lymphadenectomy on short- and long-term complications in patients with endometrial cancer
por: Proppe, Louisa, et al.
Publicado: (2022)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
por: Pelicano, Hélène, et al.
Publicado: (2014)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?
por: Dogra, Atika, et al.
Publicado: (2020)

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
por: Liedtke, Cornelia, et al.
Publicado: (2008)

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

Liver hyperplasia after tamoxifen induction of Myc in a transgenic medaka model
por: Menescal, Luciana A., et al.
Publicado: (2012)

Long-term satisfaction of patients after laparoscopic and robotic-assisted hysterectomy
por: Gitas, Georgios, et al.
Publicado: (2021)

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
por: Temian, Daiana Cosmina, et al.
Publicado: (2018)

Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
por: Proppe, L., et al.
Publicado: (2023)

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer
por: Darb-Esfahani, S, et al.
Publicado: (2012)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
por: Niwińska, Anna, et al.
Publicado: (2011)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response
por: Kreike, Bas, et al.
Publicado: (2007)

Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
por: Umekita, Yoshihisa, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vnrcjps3iqnt2jq4al0f9916v9